Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ii 200 [iu] - 480 [iu]; factor ix 200 [iu] - 310 [iu]; factor vii 100 [iu] - 250 [iu]; factor x 220 [iu] - 600 [iu]; protein c 150 [iu] - 450 [iu]; protein s precursor 120 [iu] - 380 [iu]; prothrombin complex concentrates 60mg - 140mg (includes clotting factors, protein c & protein s) - powder for injection with diluent - 250 iu - active: factor ii 200 [iu] - 480 [iu] factor ix 200 [iu] - 310 [iu] factor vii 100 [iu] - 250 [iu] factor x 220 [iu] - 600 [iu] protein c 150 [iu] - 450 [iu] protein s precursor 120 [iu] - 380 [iu] prothrombin complex concentrates 60mg - 140mg (includes clotting factors, protein c & protein s) excipient: albumin antithrombin iii heparin hydrochloric acid sodium chloride sodium citrate sodium hydroxide water for injection - treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ii 400 [iu] - 960 [iu]; factor ix 400 [iu] - 620 [iu]; factor vii 200 [iu] - 500 [iu]; factor x 440 [iu] - 1200 [iu]; protein c 300 [iu] - 900 [iu]; protein s precursor 240 [iu] - 760 [iu]; prothrombin complex concentrates 120mg - 280mg (includes clotting factors, protein c & protein s) - powder for injection with diluent - 500 iu - active: factor ii 400 [iu] - 960 [iu] factor ix 400 [iu] - 620 [iu] factor vii 200 [iu] - 500 [iu] factor x 440 [iu] - 1200 [iu] protein c 300 [iu] - 900 [iu] protein s precursor 240 [iu] - 760 [iu] prothrombin complex concentrates 120mg - 280mg (includes clotting factors, protein c & protein s) excipient: albumin antithrombin iii heparin hydrochloric acid sodium chloride sodium citrate sodium hydroxide water for injection - treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11093 - cushion, - breathable sheets to enhance seating and positioning products

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11100 - cushion, sitting, wheelchair - classic cushion for medium to high risk pressure care

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11100 - cushion, sitting, wheelchair - contour cushion for medium to high risk pressure care

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11100 - cushion, sitting, wheelchair - slimline cushion for medium to high risk pressure care

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11100 - cushion, sitting, wheelchair - sport cushion for medium to high risk pressure care

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 47476 - air-filled bed mattress overlay - medical 3 zone mattress for pressure relief

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mobility plus wheelchairs - 11100 - cushion, sitting, wheelchair - bariatric cushion

Euroopan unioni - englanti - EMA (European Medicines Agency)

baxalta innovations gmbh - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,